Glycemic Control as Primary Prevention for Diabetic Kidney Disease

2018 ◽  
Vol 25 (2) ◽  
pp. 141-148 ◽  
Author(s):  
Richard J. MacIsaac ◽  
George Jerums ◽  
Elif I. Ekinci
Keyword(s):  
Primary Prevention ◽  
Kidney Disease ◽  
Glycemic Control ◽  
Diabetic Kidney Disease ◽  
Diabetic Kidney

scholarly journals Long-term glycemic control and the rate of progression of early diabetic kidney disease

1993 ◽  
Vol 44 (4) ◽  
pp. 855-859 ◽  
Author(s):  
Richard E. Gilbert ◽  
Con Tsalamandris ◽  
Leon A. Bach ◽  
Sianna Panagiotopoulos ◽  
Richard C. O'Brien ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Glycemic Control ◽  
Diabetic Kidney Disease ◽  
Diabetic Kidney ◽  
Rate Of Progression

Mo2042 The Effect of Roux-en-Y Gastric Bypass on Glycemic Control and Diabetic Kidney Disease in the Zucker Diabetic Fatty Rat Model

2014 ◽  
Vol 146 (5) ◽  
pp. S-725
Author(s):  
Jessie A. Elliott ◽  
Karl J. Neff ◽  
Thomas A. Lutz ◽  
Caroline Corteville ◽  
Neil Docherty ◽  
...  
Keyword(s):  
Gastric Bypass ◽  
Kidney Disease ◽  
Glycemic Control ◽  
Rat Model ◽  
Diabetic Kidney Disease ◽  
Zucker Diabetic Fatty Rat ◽  
Diabetic Kidney

scholarly journals A Multidisciplinary Approach for Improving Quality of Life and Self-Management in Diabetic Kidney Disease: A Crossover Study

2020 ◽  
Vol 9 (7) ◽  
pp. 2160
Author(s):  
Nancy Helou ◽  
Dominique Talhouedec ◽  
Maya Zumstein-Shaha ◽  
Anne Zanchi
Keyword(s):  
Quality Of Life ◽  
Renal Function ◽  
Kidney Disease ◽  
Glycemic Control ◽  
Usual Care ◽  
Diabetic Kidney Disease ◽  
Self Management ◽  
Diabetic Kidney ◽  
Diet Habits

Individuals with diabetic kidney disease are at high risk of complications and challenged to self-manage. Previous research suggested that multidisciplinary approaches would improve health outcomes. This study investigated the effect of a multidisciplinary self-management approach of diabetic kidney disease on quality of life, and self-management, glycemic control, and renal function. A uniform balanced crossover design was used because it attains a high level of statistical power with a lower sample size. A total of 32 participants (aged 67.8 ± 10.8) were randomized into four study arms. In differing sequences, each participant was treated twice with three months of usual care alternated with three months of multidisciplinary management. The intervention improved the present dimension of quality of life demonstrating higher mean rank as compared to usual care (52.49 vs. 41.01; p = 0.026, 95% CI) and three self-care activities, general diet habits, diabetes diet habits, and blood sugar testing (respectively: 55.43 vs. 38.31; p = 0.002, 56.84 vs. 37.02; p = 0.000, 53.84 vs. 39.77; p = 0.008; 95% CI). Antihypertensive medication engagement was high across the study period (Mean = 95.38%, Min = 69%, Max = 100%). Glycemic control and renal function indicators were similar for the intervention and the usual care. Studies are needed to determine how the new recommended therapies for diabetic kidney disease such as SGLT2 inhibitors and GLP-1 receptor agonists impact on self-management and quality of life.

scholarly journals GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists

2020 ◽  
Vol 9 (4) ◽  
pp. 947 ◽  
Author(s):  
José Luis Górriz ◽  
María José Soler ◽  
Juan F. Navarro-González ◽  
Clara García-Carro ◽  
María Jesús Puchades ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Glycemic Control ◽  
Diabetic Kidney Disease ◽  
Renin Angiotensin System ◽  
Diabetic Patients ◽  
Diabetic Kidney ◽  
Receptor Agonists ◽  
Increased Risk ◽  
Stage Renal Disease ◽  
The Impact

Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease (CKD) and end-stage renal disease (ESKD), and diabetic kidney disease (DKD) is a major cause of morbidity and mortality in diabetes. Despite advances in the nephroprotective treatment of T2DM, DKD remains the most common complication, driving the need for renal replacement therapies (RRT) worldwide, and its incidence is increasing. Until recently, prevention of DKD progression was based around strict blood pressure (BP) control, using renin–angiotensin system blockers that simultaneously reduce BP and proteinuria, adequate glycemic control and control of cardiovascular risk factors. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are a new class of anti-hyperglycemic drugs shown to improve cardiovascular and renal events in DKD. In this regard, GLP-1RA offer the potential for adequate glycemic control in multiple stages of DKD without an increased risk of hypoglycemia, preventing the onset of macroalbuminuria and slowing the decline of glomerular filtration rate (GFR) in diabetic patients, also bringing additional benefit in weight reduction, cardiovascular and other kidney outcomes. Results from ongoing trials are pending to assess the impact of GLP-1RA treatments on primary kidney endpoints in DKD.

Sign in / Sign up

Export Citation Format

Share Document